CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Glofitamab 用于重度经治套细胞淋巴瘤患者：一项多中心真实世界病例系列
英文原题：Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.
查看英文原题
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
Glofitamab 在重度经治 MCL 中显示出令人鼓舞的活性和可控的毒性，包括作为 CAR-T 细胞治疗的桥接治疗。
研究思路结论见上方概要
背景
复发/难治性套细胞淋巴瘤（r/r MCL）尽管治疗取得了进展，仍然难以治疗。
方法
这项多中心回顾性研究纳入了10例r/r MCL患者，这些患者在glofitamab获得欧洲批准前（2023年1月至2024年5月）在奥地利和意大利的五个中心接受了glofitamab治疗。
结果
患者接受过大量既往治疗（中位既往治疗线数4.5；5/10为CAR-T 后）。中位5个周期后，9例可评估患者中7例观察到缓解，其中4/9为完全缓解。细胞因子释放综合征发生于7/10例（大多为1-2级），其中2/10为3级事件，而ICANS发生于2/10例患者，包括1例4级事件。3例患者接受glofitamab作为桥接治疗，且全部继续接受CAR-T 输注。
展开英文摘要原文
BACKGROUND
Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances.
METHODS
This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023-May 2024).
RESULTS
Patients were heavily pretreated (median 4.5 prior lines; 5/10 post-CAR-T). After a median of five cycles, responses were observed in 7/9 evaluable patients, including complete response in 4/9. Cytokine-release syndrome occurred in 7/10 (mostly Grade 1-2), including grade 3 events in 2/10, while ICANS occurred in 2/10 patients, including one Grade 4 event. Three patients received glofitamab as bridging therapy and all proceeded to CAR-T infusion.
CONCLUSION
Glofitamab showed encouraging activity and manageable toxicity in heavily pretreated MCL, including as bridging therapy to CAR-T-cell treatment. TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
论文信息
- 作者
- Rotter N、Raderer M、List A、Haslbauer F、Saini O、Egle A、Magnes T、Leisch M
- 第一作者单位
- Internal Medicine I: Hematology and Stem Cell Transplantation Hemostaseology and Medical Oncology Ordensklinikum Linz GmbH, Elisabethinen Linz Austria.Austria
- 通讯作者单位
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology Cancer Research Laboratory of the Department of Internal Medicine III Paracelsus Medical University Salzburg Austria.Austria
- 期刊
- EJHaem2026 Aug
- 原文标识
- PubMed 42466094 · DOI 10.1002/jha2.70343
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →